Post-earnings recap
Reported
Tue, Nov 12, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that TG Therapeutics is still in a development phase, with significant losses reflected in the EPS. The stock's decline of 2.82% suggests that investors were disappointed by the lack of revenue updates and the substantial EPS miss. Moving forward, the company's focus on clinical programs will be critical for its future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.69 | N/A | -89.83% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced in the quarter. They emphasized their commitment to ongoing clinical trials and product development.
Management did not provide specific insights into revenue expectations.
The company is focused on advancing its clinical programs despite the EPS miss.